Date: 2015-07-23
Type of information: Distribution agreement
Compound: Dukoral®, Vivotif®
Company: Valneva (France- Austria) PaxVax (USA - CA)
Therapeutic area: Infectious diseases
Type agreement: marketing distribution
Action mechanism: vaccine. Dukoral® is an oral vaccine indicated for active immunization against cholera and, in some countries, also indicated against ETEC (Enterotoxigenic Escherichia coli) and / or diarrhea caused by ETEC. The vaccine is indicated for adults and children from 2 years of age who will be visiting endemic/epidemic areas. In 2004, Dukoral® was granted a marketing authorization by the European commission
Vivotif® is a live attenuated typhoid fever vaccine for oral administration. It is the only oral vaccine indicated for use against Salmonella typhi, the most prevalent of the typhoid fever-causing bacteria. The vaccine is indicated for adults and children over the age of six and has an excellent track record for safety, having been on the market for more than
20 years.
Disease: cholera, typhoid
Details: * On July 23, 2015, Valneva, a leading pure-play vaccine biotech company and PaxVax, a fully integrated specialty vaccine company focused on travel, announced that they have entered into a marketing and distribution agreement for their respective travel vaccines, Dukoral® and Vivotif® .
Under the terms of the agreement, Valneva will distribute and promote PaxVax’s typhoid vaccine Vivotif® in Canada and the Nordic countries (Sweden, Norway, Denmark and Finland) while PaxVax will distribute and promote Valneva’s cholera vaccine Dukoral® in Italy, Spain and Portugal.
Valneva and PaxVax have established sales and marketing teams with broad experience in the travel vaccine industry. Valneva took over one of Sweden’s leading vaccine distributors “SBL Vaccin Distribution” through the acquisition of Dukoral® in February 2015 while PaxVax has established legal commercial infrastructure in Italy and Spain since its acquisition of Vivotif® in July 2014. Valneva also opened a fully-owned commercial infrastructure in Canada where the Dukoral® vaccine is already widely distributed.
Financial terms:
Latest news:
